Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to improving patients' lives by identifying, developing, and commercializing meaningful products that address unmet medical needs. Headquartered in Dublin, Ireland, with U.S. offices in Palo Alto, CA, and Philadelphia, PA, Jazz Pharmaceuticals employs over 875 people worldwide, fostering a highly collaborative and entrepreneurial culture.
Core Business: Jazz Pharmaceuticals focuses on three main therapeutic areas: sleep, hematology/oncology, and pain. The company's diverse product portfolio includes nine approved therapies across neuroscience and oncology indications. Notable products include Xyrem and Xywav for narcolepsy, Zepzelca for metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, Vyxeos for acute myeloid leukemia, and Epidiolex for severe forms of epilepsy, acquired through the purchase of GW Pharmaceuticals in May 2021.
Recent Achievements: In 2023, Jazz Pharmaceuticals reported strong financial performance, achieving over $3.8 billion in total revenue. The company also completed enrollment for a Phase 3 trial of Zepzelca in first-line small cell lung cancer and advanced several late-stage pipeline projects. In May 2024, the U.S. FDA accepted the Biologics License Application (BLA) for zanidatamab, a HER2-targeted bispecific antibody, with a Priority Review designation for treating biliary tract cancer.
Current Projects: Jazz Pharmaceuticals remains committed to expanding its product portfolio through R&D and strategic acquisitions. Ongoing projects include the development of zanidatamab for multiple HER2-expressing cancers, the Phase 3 trial for the combination of zanidatamab with standard chemotherapy for advanced gastric cancer, and the optimization of Epidiolex for broader epilepsy indications.
Financial Condition: As of December 31, 2023, Jazz Pharmaceuticals reported cash and cash equivalents of $1.6 billion. The company sustained a strong operational cash flow, generating $1.09 billion in 2023. Despite an outstanding long-term debt of $5.8 billion, Jazz's disciplined capital allocation supports continued investment in growth and innovation.
Partnerships: The company has key collaborations with various organizations, including BeiGene, Ltd. for the development of zanidatamab. Additionally, Jazz Pharmaceuticals has a strategic partnership with Life Science Cares to drive social impact through employee volunteerism in the U.S., reinforcing its commitment to community engagement.
Jazz Pharmaceuticals continues to innovate and advance its mission to transform lives through pioneering therapeutics in oncology and neuroscience, positioning itself as a leader in addressing complex and unmet medical needs.
Jazz Pharmaceuticals has received FDA approval for a revised label for Vyxeos (daunorubicin and cytarabine), allowing its use in treating newly-diagnosed therapy-related acute myeloid leukemia (t-AML) and AML with myelodysplasia-related changes (AML-MRC) in pediatric patients aged 1 year and older. This approval is based on safety data from two trials by the Children's Oncology Group and Cincinnati Children's Hospital, demonstrating a critical need for effective therapies in this demographic. Vyxeos is significant in the fight against AML, a rare yet serious cancer.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will participate in the 10th Annual J.P. Morgan Napa Valley Forum on March 29, 2021. CEO Bruce Cozadd will deliver a corporate presentation, including business and financial updates, at 12:00 p.m. EST. The presentation can be accessed via a live audio webcast from the company's website, with an archive available for one week post-event. Jazz focuses on developing and commercializing life-changing medicines in areas like neuroscience and oncology, serving patients in over 90 countries.
On March 18, 2021, Jazz Pharmaceuticals (Nasdaq: JAZZ) partnered with the Hypersomnia Foundation to launch the 'I Have IH' campaign. This initiative aims to raise awareness and understanding of idiopathic hypersomnia (IH), a debilitating neurologic sleep disorder. A recent survey of 305 healthcare providers revealed that only 36% believe others adequately understand IH, highlighting a significant education gap. With misdiagnosis common and delays in accurate diagnosis lasting up to 15 years, the campaign seeks to empower patients and enhance discussions with their healthcare teams.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced participation in the Cowen 41st Annual Healthcare Conference, with CEO Bruce Cozadd presenting on March 2, 2021, at 12:50 p.m. EST. The webcast will cover a business and financial update and can be accessed through their website.
Archived audio of the presentation will be available for at least a week following the event. Jazz Pharmaceuticals focuses on developing life-changing medicines in neuroscience and oncology, serving patients in over 90 countries.
Jazz Pharmaceuticals (Nasdaq: JAZZ) reported a 9% revenue increase in 2020, totaling $2.36 billion, driven by successful product launches like Zepzelca and Xywav. GAAP net income for 2020 was $238.6 million, or $4.22 per diluted share, down from $523.4 million in 2019. The company projects 2021 revenues between $2.55 billion and $2.7 billion, emphasizing growth in neuroscience and oncology sectors. Additionally, Jazz is set to acquire GW Pharmaceuticals for $7.2 billion, aiming to enhance its neuroscience portfolio.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced its participation in the Leerink 10th Annual Global Healthcare Conference. CEO Bruce Cozadd will present on February 24, 2021, at 1:40 p.m. EST. The presentation will include a business and financial update, accessible via a live audio webcast on the Jazz Pharmaceuticals website. An archive will be available for at least a week post-presentation. Jazz is focused on developing innovative medications in neuroscience and oncology, with a global presence serving patients in over 90 countries.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has completed the rolling submission for a supplemental New Drug Application (sNDA) to the FDA for Xywav™. This oral solution aims to treat adult patients with idiopathic hypersomnia, marking it as the first approved treatment in the U.S. for this condition. The application follows Fast Track designation received in September 2020 and was granted rolling submission in December 2020. Jazz plans to make this treatment available in Q4 2021, pending FDA approval. The prevalence of idiopathic hypersomnia is estimated to exceed 37,000 adults in the U.S.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will announce its 2020 fourth quarter and full year financial results on February 23, 2021, post market close. A live audio webcast will follow at 4:30 p.m. EST/ 9:30 p.m. GMT for a discussion on the results and company update. Interested parties can access the webcast on the Jazz Pharmaceuticals website. The company develops life-changing medicines in neuroscience and oncology, with a diverse portfolio serving patients in over 90 countries.
Jazz Pharmaceuticals has announced a $7.2 billion acquisition of GW Pharmaceuticals, valuing the company at $220 per American Depositary Share. The deal includes $200 in cash and $20 in Jazz shares, representing a premium of 50% over GW's recent stock price. Expected to close in Q2 2021, this acquisition aims to enhance Jazz's neuroscience portfolio with GW's lead product, Epidiolex, a treatment for severe epilepsy. The combined entity is projected to accelerate revenue growth, driven by a robust pipeline of 19 clinical programs focused on critical unmet patient needs.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will webcast its corporate presentation at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 2:00 p.m. EST. CEO Bruce Cozadd will provide a business and financial update. The live audio webcast can be accessed on the Jazz Pharmaceuticals website and will be archived for at least a week afterward. The company focuses on developing life-changing medicines in neuroscience and oncology, and operates globally, serving patients in over 90 countries.
FAQ
What is the current stock price of Jazz Pharmaceuticals (JAZZ)?
What is the market cap of Jazz Pharmaceuticals (JAZZ)?
What does Jazz Pharmaceuticals specialize in?
What are some key products of Jazz Pharmaceuticals?
Where is Jazz Pharmaceuticals headquartered?
What recent achievements has Jazz Pharmaceuticals made?
What is zanidatamab?
How financially stable is Jazz Pharmaceuticals?
What partnerships does Jazz Pharmaceuticals have?
What is Jazz Pharmaceuticals' approach to business culture?
What are the company's future plans?
How can investors stay informed about Jazz Pharmaceuticals?
